Literature DB >> 24917981

The societal gain of medical development and innovation in gastroenterology.

Caroline M den Hoed1, Kees Isendoorn2, Wouter Klinkhamer2, Anshu Gupta2, Ernst J Kuipers3.   

Abstract

BACKGROUND: Gastroenterology has over the past 30 years evolved very rapidly. The societal benefits to which this has led are incompletely determined, yet form a mandate to determine the need for future innovations and further development of the field. A more thorough understanding of societal benefits may help to determine future goals and improve decision making. AIMS: The objective of this article is to determine the societal gains of medical innovations in the field of gastroenterology in the past and future, using peptic ulcer disease as an example of past innovation and the implementation of colorectal cancer screening as an illustration of future gains.
METHODS: Literature searches were performed for data on peptic ulcer and colorectal cancer epidemiology, treatment outcomes, and costs. National and governmental databases in the Netherlands were searched to obtain the input for calculations of quality-adjusted life years (QALYs), health-adjusted life expectancy (HALE), and the corresponding societal benefit.
RESULTS: Since 1980 the improvements in peptic ulcer treatment have had a limited impact on life expectancy, rising from 83.6 years to 83.7 years, but have led to a yearly gain of 46,000 QALYs, caused by improved quality of life. These developments in the field of peptic ulcer translated into a yearly gain of 1.8 billion to 7.8 billion euros in 2008 compared with the 1980s. Mortality due to colorectal cancer is high, with 21.6 deaths per 100,000 per year in the Netherlands (European Standardized Rate (ESR)). The future implementation of a nationwide call-recall colorectal cancer screening by means of biennial fecal immunochemical testing (FIT) is expected to result in a 50%-80% mortality reduction and thus a gain of an estimated 35,000 life years per year, corresponding to 26,000 QALYs per year. The effects of the implementation of FIT screening can be translated to a future societal gain of 1.0 billion to 4.4 billion euro.
CONCLUSIONS: The innovations and developments in the field of gastroenterology have led to significant societal gains in the past three decades. This process will continue in the near future as a result of further developments. These calculations provide a template for calculations on the need for specialist training as well as research and implementation of new developments in our field.

Entities:  

Keywords:  Peptic ulcer; colon cancer; quality of life; screening; societal gain

Year:  2013        PMID: 24917981      PMCID: PMC4040771          DOI: 10.1177/2050640613502337

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  32 in total

1.  The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study.

Authors:  R Etzioni; S D Ramsey; K Berry; M Brown
Journal:  Health Econ       Date:  2001-04       Impact factor: 3.046

2.  Calculating QALYs, comparing QALY and DALY calculations.

Authors:  Franco Sassi
Journal:  Health Policy Plan       Date:  2006-07-28       Impact factor: 3.344

3.  Health impact of peptic ulcer in the United States.

Authors:  A Sonnenberg; J E Everhart
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

4.  Cost-effectiveness of colonoscopy in screening for colorectal cancer.

Authors:  A Sonnenberg; F Delcò; J M Inadomi
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

5.  Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study.

Authors:  Volker Arndt; Henrike Merx; Christa Stegmaier; Hartwig Ziegler; Hermann Brenner
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

6.  Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening.

Authors:  Nereo Segnan; Carlo Senore; Bruno Andreoni; Alberto Azzoni; Luigi Bisanti; Alessandro Cardelli; Guido Castiglione; Cristiano Crosta; Andrea Ederle; Alberto Fantin; Arnaldo Ferrari; Mario Fracchia; Franco Ferrero; Stefano Gasperoni; Serafino Recchia; Mauro Risio; Tiziana Rubeca; Giorgio Saracco; Marco Zappa
Journal:  Gastroenterology       Date:  2007-03-21       Impact factor: 22.682

7.  Time trends of ulcer mortality in Europe.

Authors:  Amnon Sonnenberg
Journal:  Gastroenterology       Date:  2007-04-14       Impact factor: 22.682

8.  Health-adjusted life expectancy.

Authors:  M C Wolfson
Journal:  Health Rep       Date:  1996       Impact factor: 4.796

9.  Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data.

Authors:  Kathleen Lang; Lisa M Lines; David W Lee; Jonathan R Korn; Craig C Earle; Joseph Menzin
Journal:  Clin Gastroenterol Hepatol       Date:  2008-09-04       Impact factor: 11.382

10.  Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force.

Authors:  Ann G Zauber; Iris Lansdorp-Vogelaar; Amy B Knudsen; Janneke Wilschut; Marjolein van Ballegooijen; Karen M Kuntz
Journal:  Ann Intern Med       Date:  2008-10-06       Impact factor: 25.391

View more
  1 in total

1.  Outcome of probe-based confocal laser endomicroscopy (pCLE) during endoscopic retrograde cholangiopancreatography: A single-center prospective study in 45 patients.

Authors:  Johannes-Matthias Löhr; Ragnar Lönnebro; Serena Stigliano; Stephan L Haas; Fredrik Swahn; Lars Enochsson; Rozh Noel; Ralf Segersvärd; Marco Del Chiaro; Caroline S Verbeke; Urban Arnelo
Journal:  United European Gastroenterol J       Date:  2015-12       Impact factor: 4.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.